PANOVA-3: A phase III study of TTFields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC)

被引：0
|
作者：
Weinberg, Uri [1 ]
Farber, Ori [2 ]
Giladi, Moshe [2 ]
Bomzon, Zeev [2 ]
Lavy-Shahaf, Gitit [2 ]
Kirson, Eilon D. [2 ]
机构：
[1] Novocure GmbH, Root, Switzerland
[2] Novocure, Haifa, Israel
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT157
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [42] Sequential neoadjuvant chemotherpy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): A PILOT study.
    Kunzmann, Volker
    Hartlapp, Ingo
    Scheurlen, Michael
    Einsele, Hermann
    Mueller, Justus
    Kenn, Werner
    Steger, Ulrich
    Germer, Christoph T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
    Tempero, M.
    Oh, D-Y
    Tabernero, J.
    Reni, M.
    Van Cutsem, E.
    Hendifar, A.
    Waldschmidt, D-T
    Starling, N.
    Bachet, J-B
    Chang, H-M
    Maurel, J.
    Garcia-Carbonero, R.
    Lonardi, S.
    Coussens, L. M.
    Fong, L.
    Tsao, L. C.
    Cole, G., Jr.
    James, D.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 600 - 608
  • [44] FOLFIRINOX and Gemcitabine/nab-Paclitaxel Demonstrate Improved Survival in Locally Advanced Unresectable Pancreatic Adenocarcinoma
    Bednar, F.
    Ocuin, L.
    Steve, J.
    Zenati, M.
    Winters, S.
    Hogg, M.
    Bahary, N.
    Zeh, H., III
    Zureikat, A.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S175 - S176
  • [45] PANOVA: a phase II study of TTFields (150 kHz) with concomitant standard chemotherapy for front-line advanced pancreatic adenocarcinoma: Updated efficacy results
    Kueng, M.
    Guillen-Ponce, C.
    Rivera Herrero, F.
    J., Gallego Plazas
    Lopez-Martin, J. A.
    Benavides, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Neoadjuvant nab-paclitaxel and gemcitabine (AG) in borderline resectable (BR) or unresectable (UR) locally advanced pancreatic adenocarcinoma (LAPC) in patients ineligible for FOLFIRINOX
    Peterson, Shawn
    Loaiza-Bonilla, Arturo
    Ben-Josef, Edgar
    Drebin, Jeffrey A.
    Westendorf-Overley, Colleen
    Anthony, Lowell Brian
    DeSimone, Philip A.
    Goel, Gaurav
    Kudrimoti, Mahesh R.
    Dineen, Sean Patrick
    Tzeng, Ching-Wei David
    Hosein, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [47] International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT
    Philip, P.
    Kayitalire, L.
    Nydam, T.
    Penenberg, D.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2015, 26
  • [48] The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
    Dean, A.
    Das, A.
    McNulty, M.
    Travers, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Development of extensive hepatic steatosis during treatment with nab-paclitaxel and gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma
    Vogl, U. M.
    Vormittag, L.
    Kafka, A.
    Heinrich, B.
    Roessler, L.
    Stuebler, J.
    Schima, W.
    Oehler, L.
    ONKOLOGIE, 2013, 36 : 74 - 74
  • [50] A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    ONCOLOGIST, 2023, 28 (07): : E575 - E584
12345